

October 2, 2012

Pharmacy Announcement

Preferred Drug List (PDL) Changes Effective June 1, 2012

On March 22, 2012, the Pharmacy and Therapeutics (P&T) Committee of the Nevada Department of Health and Human Services' Division of Health Care Financing and Policy met to review new and existing therapeutic drug classes on the Nevada Medicaid Preferred Drug List (PDL).

The actions taken by the committee are indicated below. All changes were effective June 1, 2012. The complete PDL is posted on the "[Preferred Drug List](#)" webpage.

Drug Class	Drugs Added	Drugs Removed	Drugs Reviewed But Not Added
Angiotensin II Receptor Blockers and Diuretic Combinations	None	None	Edarbi®
Anticoagulants: Oral	Warfarin, Coumadin®, Jantoven®, Xarelto®	None	Pradaxa®
Cardiovascular: Direct Renin Inhibitors and Combinations	Tekamlo®	None	Amturnide®
Diabetic Agents: DPP-4 Inhibitors and Combinations	Kombiglyze XR®, Tradjenta®	None	Bydureon®
Hepatitis C Agents – Antivirals: Hepatitis C Protease Inhibitors	Incivek®	None	Victrelis®
Ophthalmic Antihistamines	Bepreve®	None	Lastacraft®
Ophthalmic Non-Steroidal Anti-Inflammatory Agents	None	None	Bromday®
Ophthalmic Quinolones	Ofloxacin®, Moxeza®	None	Besivance® Zymaxid®
Respiratory: Inhaled Corticosteroid/Beta-Adrenergic Combinations	None	None	Dulera®
Respiratory: Oral COPD Agents	Daliresp®	None	None